Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | DNM1 | Q05193 | 4/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA3 | P07451 | 2/20 | 0.42 |
| ▸ | CA4 | P22748 | 2/20 | 0.42 |
| ▸ | CA6 | P23280 | 2/20 | 0.42 |
| ▸ | CA5A | P35218 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7523529 | 1.00 | CHRM2 (0.46) | CHRM2DNM1CA12CA1CA2 | |
| SCHEMBL29837911 | 1.00 | CHRM2 (0.46) | CHRM2DNM1CA12CA1CA2 | |
| SCHEMBL9190540 | 1.00 | CHRM2 (0.46) | CHRM2DNM1CA12CA1CA2 | |
| SCHEMBL29198096 | 0.97 | CHRM2 (0.42) | CHRM2DNM1CA12CA1CA2 | |
| SCHEMBL3077794 | 0.97 | CHRM2 (0.42) | CHRM2DNM1CA12CA1CA2 | |
| SCHEMBL30186917 | 0.95 | CHRM2 (0.40) | CHRM2DNM1CA12CA1CA2 | |
| Trolamine SCHEMBL28176957 | 0.95 | DNM1 (0.47) | CHRM2DNM1CA12CA1CA2 | |
| SCHEMBL28333383 | 0.90 | CHRM2 (0.46) | CHRM2DNM1CA12CA1CA2 | |
| SCHEMBL1674639 | 0.89 | TSHR (0.39) | CHRM2DNM1CA12CA1CA2 | |
| SCHEMBL11591877 | 0.89 | TSHR (0.39) | CHRM2DNM1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3390344-B1 | IMPROVED METHOD FOR SYNTHESISING PARTIALLY N-HYDROXYETHYLATED TERTIARY 1,6-HEXANEDIAMINES | IFP ENERGIES NOW (FR) | 2020-12-02 | — | — | EP | claimed |
| US-10618866-B2 | Method for synthesising partially N-hydroxyethylated tertiary 1,6-hexanediamines | IFP Energies Nouvelles (FR) | 2020-04-14 | — | — | US | claimed |
| US-20190002392-A1 | IMPROVED METHOD FOR SYNTHESISING PARTIALLY N-HYDROXYETHYLATED TERTIARY 1,6-HEXANEDIAMINES | IFP Energies Nouvelles (FR) | 2019-01-03 | — | — | US | claimed |
| EP-4644507-A1 | RUBBER COMPOSITION FOR SEAL MATERIAL | VALQUA, Ltd. (JP) | 2025-11-05 | — | — | EP | disclosed |
| US-20250109277-A1 | CYCLIC OLEFIN RESIN COMPOSITION, MOLDED ARTICLE, AND OPTICAL COMPONENT | MITSUI CHEMICALS, INC. (JP) | 2025-04-03 | — | — | US | disclosed |
| WO-2024142767-A1 | RUBBER COMPOSITION FOR SEAL MATERIAL | 株式会社バルカー | 2024-07-04 | — | — | WO | disclosed |
| WO-2023153302-A1 | CYCLIC OLEFIN RESIN COMPOSITION, MOLDED ARTICLE AND OPTICAL COMPONENT | 三井化学株式会社 | 2023-08-17 | — | — | WO | disclosed |
| US-10967325-B2 | Absorbent solution based on hydroxyl derivatives of 1,6-hexanediamine and method for eliminating acid compounds from a gaseous effluent | IFP Energies Nouvelles (FR) | 2021-04-06 | — | — | US | disclosed |
| EP-3390344-B1 | IMPROVED METHOD FOR SYNTHESISING PARTIALLY N-HYDROXYETHYLATED TERTIARY 1,6-HEXANEDIAMINES | IFP ENERGIES NOW (FR) | 2020-12-02 | — | — | EP | disclosed |
| US-20200323889-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2020-10-15 | — | — | US | disclosed |
| US-20200254380-A1 | ABSORBENT SOLUTION BASED ON HYDROXYL DERIVATIVES OF 1,6-HEXANEDIAMINE AND METHOD FOR ELIMINATING ACID COMPOUNDS FROM A GASEOUS EFFLUENT | IFP Energies Nouvelles (FR) | 2020-08-13 | — | — | US | disclosed |
| US-20020182581-A1 | Treating blood or blood products with compounds which have a mustard, aziridinium or aziridine group and a nucleic acid binding group | CERUS CORPORATION (US) | 2002-12-05 | — | — | US | disclosed |
| US-6410219-B1 | DECTIONN OF PATHOGEN DEACTION OF PATHOGEN BY COMPLEXING | CERUS CORPORATION | 2002-06-25 | — | — | US | disclosed |
| US-6171777-B1 | DECONTAMINATING BY CONTACTING WITH COMPOUND, THEN RECOVERING PRODUCT; DEACTIVATES HUMAN IMMUNODEFICIENCY AND HEPATITIS VIRUSES; BEFORE TRANSFUSIONS OR CLINICAL TESTS | CERUS CORPORATION | 2001-01-09 | — | — | US | disclosed |
| US-6143490-A | IN VITRO METHOD FOR DEACTIVATION OF VIRAL, BACTERIAL, OR PROTOZOAN PATHOGEN BY ADDING COMPOUND CONSISTING OF INTERCALATOR NUCLEIC ACID BINDING LIGAND AND AN ATTACHED MUSTARD GROUP, TREATING THE MIXTURE, AND RECOVERING BLOOD | CERUS CORPORATION (US) | 2000-11-07 | — | — | US | disclosed |
| EP-0773716-A4 | TREATING RED BLOOD CELL SOLUTIONS WITH ANTI-VIRAL AGENTS | CERUS CORP (US) | 1999-08-04 | — | — | EP | disclosed |
| EP-0888283-A1 | WIDELY-BRIDGED ALCOHOL POLYETHOXYLATES AND THEIR USE | ALBEMARLE CORPORATION (US) | 1999-01-07 | — | — | EP | disclosed |
| WO-1998014422-A1 | WIDELY-BRIDGED ALCOHOL POLYETHOXYLATES AND THEIR USE | ALBEMARLE CORPORATION (US) | 1998-04-09 | — | — | WO | disclosed |
| EP-0773716-A1 | TREATING RED BLOOD CELL SOLUTIONS WITH ANTI-VIRAL AGENTS | Cerus Corporation (US) | 1997-05-21 | — | — | EP | disclosed |
| WO-1996039818-A1 | TREATING RED BLOOD CELL SOLUTIONS WITH ANTI-VIRAL AGENTS | CERUS CORPORATION (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190002392-A1 | IMPROVED METHOD FOR SYNTHESISING PARTIALLY N-HYDROXYETHYLATED TERTIARY 1,6-HEXANEDIAMINES | BHMT2, DNMT1, DNMT3A | CHRM2 490/4885DNM1 2488/4885CA12 4587/4885 |
| US-20020182581-A1 | Treating blood or blood products with compounds which have a mustard, aziridinium or aziridine group and a nucleic acid binding group | ADAR, CD99, AAAS | CHRM2 4623/4885DNM1 3633/4885CA12 1068/4885 |
| US-10967325-B2 | Absorbent solution based on hydroxyl derivatives of 1,6-hexanediamine and method for eliminating acid compounds from a gaseous effluent | HAAO, HPD, ALKBH1 | CHRM2 122/4885DNM1 2420/4885CA12 2445/4885 |
| US-20200254380-A1 | ABSORBENT SOLUTION BASED ON HYDROXYL DERIVATIVES OF 1,6-HEXANEDIAMINE AND METHOD FOR ELIMINATING ACID COMPOUNDS FROM A GASEOUS EFFLUENT | HAAO, HPD, ALKBH1 | CHRM2 122/4885DNM1 2420/4885CA12 2445/4885 |
| US-10618866-B2 | Method for synthesising partially N-hydroxyethylated tertiary 1,6-hexanediamines | BHMT2, DNMT1, HNMT | CHRM2 489/4885DNM1 2507/4885CA12 4574/4885 |
| US-20200323889-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | PSMG3, COPB1, PSMA6 | CHRM2 4714/4885DNM1 2474/4885CA12 1452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.